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The hypothesis that diabetes mellitus (DM) 
is associated with an increased risk of can-
cer is a deep-rooted suggestion, formu-
lated probably during nineteenth century, 
surely very far away from knowledge of the 
pathogenic mechanisms of both diseases. 
Nowadays, numerous meta-analysis dem-
onstrate the strong positive correlation 
existing between DM and site-specific can-
cer. In addition, patients developing cancer 
with pre-existing DM are reported to expe-
rience higher short- and long-term mor-
tality. Anyway, the increased risk of cancer 
development in subjects with an alteration 
of glucose metabolism is not yet explained: 
this lack could be addressed to the over-
lapping risk factors of both diseases like 
physical inactivity and overalimentation 
or to the confounding factor represented 
by anti-diabetic treatments.
The strongest association between DM 
and site-specific cancer regards liver and 
pancreatic cancer. Liver cells are exposed 
to high levels of insulin and, consequently, 
to its mitogenic effect due to portal cir-
culation. However, this event occurs both 
in diabetic and non-diabetic subjects, so 
limiting the relevance of this mechanism 
to explain the high frequency of liver can-
cer in DM. On the other hand, diabetic 
patients are more prone to develop cirrho-
sis, steatosis, and non-alcoholic fatty liver 
disease (NAFLD) and these conditions 
are surely correlated to liver cancer. The 
relationship between DM and pancreatic 
cancer is very difficult to prove because it 
is arduous to establish which condition 
begins firstly between cancer or hyper-
glycemia (like the question of the chicken 
and the egg). However, lots of reported 
findings give support to consider DM as 
risk factor for pancreatic cancer; actually, 
deeper researches are necessary to clarify 
the mechanism and the implication of this 
intriguing connection.
Another of the main site-specific cancer 
frequently associated with DM is breast can-
cer (BC), the most common cause of death 
due to cancer in European women. Around 
one in five women with BC is affected also 
by DM and probably their coexistence 
could be explained by similar risk factors 
like obesity, dyslipidemia, and hyperinsu-
linemia, although the mechanism under-
lying this articulated relation needs to be 
clarify. Several longitudinal and retrospec-
tive cohort studies demonstrate that the 
frequency of BC is significantly increased 
in postmenopausal women with DM; fur-
thermore, they reveal that the prognosis 
of women with BC and DM is worse and 
overall mortality is higher in comparison 
with non-diabetic patients.
An increase of the development of other 
organ cancers in correlation with DM is 
reported, although in some cases studies are 
not so numerous or well built. They include 
endometrial, colorectal, and bladder cancer 
in which the most recent evidence under-
line not only a raise in the prevalence in 
the cohort of patients with DM but also an 
increased mortality.
As all the rules that must be respected, 
the positive correlation between DM and 
cancer has an exception represented by 
prostate cancer. In contrast with the other 
evidences, in fact, recent meta-analysis 
report a reduced frequency of prostate 
cancer in men affected by DM. Even 
though insulin can play a role also in the 
progression and the prognosis of this spe-
cific cancer, especially during the andro-
gen deprivation therapy, diabetes-related 
hypogonadism seems to represent the piv-
otal determining of the decreased risk of 
developing this neoplasm.
Focusing on the possible pathogenic 
mechanism that sustained this linkage, the 
metabolic disequilibrium that characterize 
a diabetic person contains various elements 
of interest able to explain several aspects of 
the increased risk of neoplasm or tumoral 
progression in these patients. These are 
represented by hyperglycemia, hyperinsu-
linemia and insulin resistance, obesity and 
chronic inflammation which are singularly 
or contemporary present in DM.
By definition, cancer cells have a very 
sustained proliferation and need more glu-
cose than other cells; DM and correlated 
hyperglycemia are optimal conditions for 
sustaining this metabolic change occurring 
in cancer cells, that, opportunely, increase 
the expression of glucose membrane trans-
porters. This abnormal activation of glucose 
catabolism leads to an increased production 
of lactate that reduced ph of extracellular 
matrix, causing the death of non-tumoral 
cells and promoting the activation of matrix 
collagenases which make easier the develop-
ment of metastasis. In addition, hypergly-
cemia cause the accumulation of advanced 
glycation end-products (AGEs) which are 
responsible for oncogenic DNA damaging 
through the production of reactive oxygen 
species (ROS).
In non-type I DM, insulin levels are 
almost always elevated upon the upper 
range limit and it is associated with the 
intensification of its pro-proliferative 
effect. Several studies in literature confirm 
the mitogenic effect of insulin that could 
be considered as a peculiar growth fac-
tor; this peculiarity became stronger if we 
consider that insulin can activate non-only 
its proper receptor (IR), which results in 
anti-apoptotic activities, but also insulin-
like growth factor 1 receptor (IGF-1R) 
whose pathway play an essential role in 
cell multiplication and immortalization. 
The importance of the function of insulin 
in the development of cancer in diabetic 
patients is confirmed by the significantly 
increased expression of IR and IGF-1R in 
tumoral cells.
A significant percentage of patients 
affected by DM has a BMI compatible 
with the diagnosis of obesity. Apart from 
the induced hyperinsulinemia and insulin 
resistance, typical in these patients, pep-
tide hormones secreted by adipose tissue 
can represent the keystones to explain the 
mechanism by which obesity favors cancer 
in diabetic patients. Adiponectin and leptin 
are in fact probably involved in regulating 
carcinogenesis; the first has an anti-inflam-
matory activity and stimulate the glucose 
metabolism, increasing the insulin sensi-
tivity. Leptin, on the other hand, is been 
demonstrated having a pro-inflammatory 
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involved. But, in the third millenium medi-
cine, all the scientist are called to make an 
effort in order to give a solution to the 
emerging health questions of our society. 
This is the mission they are expected to 
accomplish.
I am hopeful.
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effect which finally results in the stimulation 
of neoplastic transformation, cell prolifera-
tion, and neo-angiogenesis.
The multiform relation between DM 
and cancer is far away to be definitively 
understood and all the studies of the next 
years will have to reckon with the complex-
ity of both DM and neoplasms and con-
sider the heterogeneity of the   population 
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